Mustang Bio, INC 8-K filings

Mustang Bio has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Mustang Bio, Inc. announced the termination of its CD20 CAR-T license agreement with Fred Hutch, settling payables for $730,000, and approved significant increases to its employee stock plans at its annual meeting.

The U.S. Food and Drug Administration has granted Orphan Drug Designation to a novel CAR T-cell therapy for recurrent diffuse and anaplastic astrocytoma and glioblastoma, providing significant incentives for its development.

Mustang Bio announces it has regained compliance with Nasdaq's minimum stockholders' equity requirement and meets all requirements for continued listing.

Mustang Bio finalizes the sale of fixed assets and exits its Worcester manufacturing facility to AbbVie for $1.0 million, relocating its headquarters and expecting $2.0 million in lease-related savings over the next 24 months.

Mustang Bio, Inc. obtained shareholder approval via written consent for the issuance of up to 5,475,082 common shares related to outstanding warrants, satisfying Nasdaq Listing Rule 5635(d).

Mustang Bio sells furniture, fixtures, and equipment to AbbVie for $1 million and terminates its lease agreement, potentially saving $2 million in lease-related payments.

Mustang Bio successfully closes an $8 million public offering and regains compliance with Nasdaq's minimum bid price requirement.

Mustang Bio enacts a 1-for-50 reverse stock split to meet Nasdaq's minimum bid price requirement, effective January 15, 2025.

Mustang Bio obtained shareholder consent to issue up to 34,767,934 common shares related to outstanding warrants.

Mustang Bio successfully held its 2024 annual meeting, electing seven directors and ratifying KPMG LLP as its independent auditor for the year ending December 31, 2024.

Mustang Bio has been granted an extension to regain compliance with Nasdaq listing rules, while also seeing the resignation of its Interim CFO and appointment of the CEO as interim CFO.

Mustang Bio has announced December 26, 2024, as the date for its annual shareholder meeting and established deadlines for submitting shareholder proposals and director nominations.

Mustang Bio has entered into an agreement for the exercise of existing warrants, generating approximately $4 million in gross proceeds and issuing new warrants for future stock purchases.

Mustang Bio has received a delisting notice from Nasdaq after failing to meet the minimum stockholders' equity requirement, and intends to request a hearing to appeal the decision.

Mustang Bio has repurchased its cell and gene therapy manufacturing assets from uBriGene for $1.395 million, reversing a previous sale due to national security concerns.

Mustang Bio has successfully completed a $2.5 million registered direct offering priced at-the-market, alongside a concurrent private placement of warrants.

Mustang Bio has entered into a new agreement to sell up to $5.6 million in common stock and terminated a prior agreement that allowed for up to $100 million in sales.

Mustang Bio has received a second notice from Nasdaq for failing to maintain a minimum share price of $1.00, adding to existing concerns about the company's compliance with listing requirements.

Mustang Bio has successfully closed a public offering, raising approximately $4 million, with potential for an additional $12 million through warrant exercises.

Mustang Bio estimates its cash and cash equivalents at approximately $1.3 million as of March 31, 2024, with $5.3 million used in operating activities for the first quarter.

Mustang Bio is reducing its workforce by approximately 81% to cut costs and preserve capital due to a challenging fundraising environment and uncertainty surrounding the sale of its cell processing facility.

Mustang Bio's sale of its cell processing facility to uBriGene is undergoing a second 45-day investigation period by the Committee on Foreign Investment in the United States (CFIUS) after multiple re-filings.

Mustang Bio has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Mustang Bio reported its full-year 2023 financial results, highlighting progress in its clinical programs and strategic corporate activities.

Mustang Bio and uBriGene have re-filed their joint voluntary notice with the U.S. Committee on Foreign Investment in the United States (CFIUS) for the sale of Mustang Bio's cell processing facility, marking the second time they've re-filed due to ongoing national security concerns.

Mustang Bio has appointed James Murphy as its Interim Chief Financial Officer, effective January 19, 2024.